HELICOBACTER PYLORI UREASE ORAL VACCINE

这项建议的目的是确定口头治疗的可行性。 重组幽门螺杆菌尿素酶免疫。 这一目标将通过口服细菌免疫和特异性免疫来检验 携带重组尿素酶融合蛋白的无病原体小鼠 旨在激发粘膜免疫反应的配方。胃病 对接种疫苗的免疫反应将得到确认。保护将 通过用H.Felis进行胃刺激来评估。 幽门螺杆菌感染人类可引起慢性胃炎 和消化性溃疡疾病。目前对这些疾病的治疗 涉及到使用化合物来减少胃酸以及 根除细菌的抗生素疗法。这些方法有 取得的成功有限，疾病的复发很常见。 预防这些微生物感染的免疫接种是一种新的方法。 预防这些疾病的发生，而不是依赖于 略微有效的治疗。 这些初步实验的结果将为 在非人类灵长类动物中进行的第二阶段实验 确认接种幽门螺杆菌疫苗在预防中的效果 胃部。

The goal of this proposal is to determine the feasibility of oral vaccination with recombinant Helicobacter pylori urease. This goal will be tested by the oral immunization of germ and specific pathogen free mice with recombinant urease fusion proteins in formulations designed to elicit mucosal immune responses. The gastric immune response to the vaccination will be confirmed. Protection will be assessed by gastric challenge with H. felis. H. pylori infections of humans have been shown to cause chronic gastritis and peptic ulcer disease. Treatment of these conditions currently involves the use of compounds to reduce stomach acid as well as antibiotic therapies to eradicate the bacterium. These approaches have been met with limited success and recurrence of disease is common. Immunization to prevent infection by these organisms is a novel approach to prevent the occurrence of these diseases rather than reliance on marginally effective treatments. The results of these preliminary experiments will provide a basis for Phase II experiments in non-human primates using direct challenge with H. pylori to confirm the efficacy of vaccination in the prevention gastric.